Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Electra Battery Materials Corporation is progressing with the construction of Canada’s only cobalt sulfate refinery in Ontario as part of its strategic plan to strengthen North America's critical minerals supply chain. The company is actively engaging with investors, industry participants, and government bodies through multiple September conference…
Rekor Systems, Inc. has terminated its two remaining long-term real estate leases in the US and Israel, resulting in elimination of ongoing rent obligations and generating over $2 million in annual cost savings. The company used $2.8 million in cash to reduce $10 million in lease liabilities, improving operating leverage and aligning cost structure…
TG Therapeutics announced that CEO Michael S. Weiss will participate in a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026. The company is a commercial-stage biotech focused on treatments for B-cell diseases, with its FDA-approved drug BRIUMVI for relapsing multiple sclerosis.
Structure Therapeutics, a clinical-stage biopharmaceutical company focused on oral small molecule therapeutics for metabolic diseases, will participate in three leading healthcare investment conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and Bernstein’s Healthcare Forum. Management will hold fir…
Crescent Biopharma, a clinical-stage biotech company focusing on innovative cancer therapies, announced its management will present at the 2026 Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference in September. The presentations will highlight the company's pipeline developments including a PD-1 x VEGF bispecific anti…
The FDA has granted Fast Track designation to Liquidia Corporation's inhaled powder drug YUTREPIA (treprostinil) for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a condition with significant unmet medical need and no approved therapies in the United States. This designation will help expedite the development an…
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York. The company is advancing its clinical-stage programs for proprietary serotonergic agonists aimed at treating depression and anxiety, including a Phase 3 candidate with FDA Breakthrough Therapy Designation…
Hillman Solutions Corp., a leading hardware product provider, has completed its acquisition of Kanebridge, LLC, a master distributor of industrial fasteners, for approximately $315 million. This strategic move significantly expands Hillman's industrial addressable market to around $3 billion and establishes its first U.S. master distribution platfo…
American Express remains a premium payment network and card issuer: high ROE, strong free cash flow, and a durable merchant network support a buy. Valuation is rich but not irrational relative to fundamentals. This trade idea proposes a mid-term position with a conservative stop and a realistic target that captures a re-rating back toward the 52-we…
Obsidian Energy (OBE) is showing constructive technicals, has solid liquidity after recent asset moves, and is trading below $1B market cap. With the stock at $12.20, multiple catalysts and a tight trade plan offer a favorable risk/reward for a mid-term swing trade over the next 45 trading days.
Micron is sitting on the economic winners of the AI build-out: HBM and data-center DRAM. Balance-sheet strength, $26.2B in free cash flow, and near-term sell-side estimates that imply $50.8B of revenue for the quarter support a bullish trade into Q4 2026. This trade idea outlines an entry, stop, and target with a 45-trading-day horizon designed to …
Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for its unified technology platform that addresses healthcare fragmentation by integrating consumer experiences, clinician workflows, care programs, and partner solutions. The award highlights Amwell’s innovation and business impact in creating a connected infrastr…
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026. The company is preparing for a Phase 3 pivotal trial for its lead drug ATH434, which has shown promising results in Phase 2 trials for Multiple Sy…
Polestar said on Sept. 3 that it has lowered its full-year delivery forecast after U.S. authorities barred the China-linked automaker from selling vehicles in the United States from model year 2027 onwards. The decision comes as the company reported weaker revenue, narrowed losses versus a year earlier, significant restructuring charges tied to its…
Azimut Holding SpA rose 3.6% to €39.26 after Deutsche Bank upgraded the stock to 'buy' and lifted its 12-month price target to €46 from €35. The upgrade cited strong first-half 2026 results, including double-digit recurring revenue and recurring net profit growth and record assets under management, along with a new share buyback and a capital retur…
Aurora Mobile Limited showcased its AI solution portfolio at the AI Expo Summer 2026 in Tokyo, featuring EngageLab, GPTBots.ai, and Modellix.ai platforms designed to enhance customer engagement, support automation, and AI media generation. The company's modular AI solutions attracted strong interest from multiple sectors including financial service…
BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on innovative small molecule cancer treatments, will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted its leading programs including BH-30643, a Fast Track designated dr…
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company listed on Nasdaq, announced that its management will participate in two significant healthcare investor conferences in September 2026: the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference. The company focuses on developing small-molecule therapeuti…
Cartesian Therapeutics, a late clinical-stage biotech company focused on cell therapies for autoimmune diseases, announced its participation in several key investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Healthcare, and H.C. Wainwright. The company will discuss its lead CAR-T therapeutic candidates in vari…
Fate Therapeutics announced management's participation in a fireside chat at the upcoming 2026 Annual Cantor Global Healthcare Conference to discuss its iPSC-derived off-the-shelf CAR T-cell product candidate FT819, recent clinical progress including the start of the Phase 2 RECLAIM-LN trial for lupus nephritis, and the unique safety profile of FT8…
Eledon Pharmaceuticals announced multiple milestones for its lead drug candidate tegoprubart, including IND submission to FDA for an islet cell transplantation trial, enrollment of first patients in investigator-initiated studies, compassionate use dosing in transplant patients with renal dysfunction and high sensitization, and reaffirmed plans to …
C4 Therapeutics announced it will present new biomarker data demonstrating the immunomodulatory effects of its investigational drug cemsidomide, combined with dexamethasone, from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd International Myeloma Society Annual Meeting. The data highlights the drug's impact on T and NK cells, s…
LeonaBio, a clinical-stage biopharmaceutical company listed on NASDAQ, announced its participation in the Cantor Global Healthcare Conference 2026. Management will engage in a fireside chat to discuss their novel therapeutic developments targeting diseases with high unmet medical needs, including metastatic breast cancer and ALS. The event will fea…
Climb Bio announced positive Phase 1 trial data for its anti-APRIL monoclonal antibody, CLYM116, showing a ~29-day half-life and sustained APRIL suppression with favorable safety. The data supports an every-12-week dosing regimen for treating IgA nephropathy. The Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027, and a Phase…
Breckenridge Distillery, a craft spirits brand under Tilray Brands, announced an expanded distribution partnership with Southern Glazer’s Wine & Spirits in New York and California. This expansion aims to increase market penetration and consumer access to its broad portfolio including bourbon, vodka, and ready-to-drink offerings in two of the larges…
